E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Lilly aims to advance treatments for serious autoimmune and allergic diseases with the Merida acquisition. The transaction is expected to close in the fourth quarter of 2026.
imphoenix82
Roche has announced that the US Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng (satralizumab) as a potential treatment for thyroid eye disease (TED). TED, also known as Graves’ ophthalmopathy, is a rare autoimmune inflammatory disease that affects the area around the eyes […]
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
